Email Address
info@myglp1store.com
Phone Number
+1 470-535-5258
Our Location
8102 Blanding blvd. Jacksonville, FL 32244
info@myglp1store.com
+1 470-535-5258
8102 Blanding blvd. Jacksonville, FL 32244
Price range: $119.00 through $149.99
✅ What the clinical trials show
In a Phase 2 trial in adults with overweight/obesity, participants received once-weekly subcutaneous doses of Survodutide ranging from 0.6 mg to 4.8 mg, with some groups undergoing gradual titration, compared to placebo, for up to 46 weeks.
The highest-dose group (4.8 mg) achieved a mean weight reduction of approximately –14.9% at 46 weeks (placebo-adjusted ~–12.1%).
Dosing in trials was once weekly, subcutaneous injection.
Sample titration schedule (research context only)
Based on trial protocols and study designs:
Weeks 1–20: ~0.6 mg weekly initially, gradually increasing toward ~2.4–3.6 mg
Weeks 21–46: ~2.4 mg / 3.6 mg / 4.8 mg weekly for maintenance at target levels
Phase 3 design: escalation to up to ~6.0 mg weekly is being studied in ongoing trials
⚠️ Important cautions
Survodutide is not approved for weight loss in general clinical practice.
The doses above are derived from clinical trial settings only and are not official prescribing guidelines.
Long-term safety, optimal maintenance dosing, and higher-dose effects beyond the studied ranges are not fully established.
Most common side effects in trials were gastrointestinal (nausea, vomiting); discontinuation occurred in ~25% of treated participants versus ~4% of placebo.
Any off-trial use or dose escalation beyond the studied range carries significant safety, ethical, and legal risks.
This product is intended for research purposes only. It is designated strictly for in vitro testing and laboratory experimentation and is not approved for human or animal consumption. All information provided on this website is for educational and informational purposes only. This product should be handled only by licensed and qualified professionals. It is not a drug, food, or cosmetic, and must not be misbranded, misused, or mislabeled as such.
Experience the science of transformation with Survodutide, an advanced peptide formulation developed to promote effective weight control and fat metabolism. Acting as a dual GLP-1 and GIP receptor agonist, this compound helps balance appetite, stabilize blood sugar levels, and support healthy energy utilization — making it a powerful ally in your fitness or wellness journey.
At MYGLP1 Store, we provide authentic Survodutide Peptides from verified suppliers, ensuring exceptional quality and purity. Designed for individuals pursuing healthier body composition and improved metabolic performance, this product offers professional-grade benefits with convenient online access.
Encourages gradual, sustainable weight management
Supports reduction of stored body fat
Helps reduce appetite and overeating tendencies
Promotes better glucose control and insulin sensitivity
Aids in maintaining long-term metabolic balance
Premium, lab-tested Survodutide sourced from trusted facilities
Fast and secure shipping with discreet packaging
Professional customer support and responsive service
Safe online ordering and satisfaction guarantee
This peptide mimics the natural actions of GLP-1 and GIP hormones, signaling your body to control hunger while improving fat oxidation. Over consistent use, it may help users achieve visible body transformation results when combined with balanced nutrition and physical activity.
Survodutide should be used under professional supervision for research or therapeutic purposes. Always consult your healthcare provider before starting any peptide-based program.
Empower your wellness goals with Survodutide — a trusted peptide for balanced weight loss and fat reduction.
Order online from MYGLP1 Store today for quality, reliability, and fast delivery.
✅ What the clinical trials show
In a Phase 2 trial in adults with overweight/obesity, participants received once-weekly subcutaneous doses of Survodutide ranging from 0.6 mg to 4.8 mg, with some groups undergoing gradual titration, compared to placebo, for up to 46 weeks.
The highest-dose group (4.8 mg) achieved a mean weight reduction of approximately –14.9% at 46 weeks (placebo-adjusted ~–12.1%).
Dosing in trials was once weekly, subcutaneous injection.
Sample titration schedule (research context only)
Based on trial protocols and study designs:
Weeks 1–20: ~0.6 mg weekly initially, gradually increasing toward ~2.4–3.6 mg
Weeks 21–46: ~2.4 mg / 3.6 mg / 4.8 mg weekly for maintenance at target levels
Phase 3 design: escalation to up to ~6.0 mg weekly is being studied in ongoing trials
⚠️ Important cautions
Survodutide is not approved for weight loss in general clinical practice.
The doses above are derived from clinical trial settings only and are not official prescribing guidelines.
Long-term safety, optimal maintenance dosing, and higher-dose effects beyond the studied ranges are not fully established.
Most common side effects in trials were gastrointestinal (nausea, vomiting); discontinuation occurred in ~25% of treated participants versus ~4% of placebo.
Any off-trial use or dose escalation beyond the studied range carries significant safety, ethical, and legal risks.
